- Home
- VNRX
VNRX
VolitionRX Limited
as 09-05-2025 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 68.3M | IPO Year: | N/A |
| Target Price: | $3.50 | AVG Volume (30 days): | 191.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $0.94 | Next Earning Date: | 08-14-2025 |
| Revenue: | $1,319,252 | Revenue Growth: | 35.10% |
| Revenue Growth (this year): | 274.46% | Revenue Growth (next year): | 212.60% |
Stock Insider Trading Activity of VolitionRX Limited (VNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Reynolds Cameron John | VNRX | President and CEO | Jun 12 '25 | Buy | $0.59 | 12,500 | $7,372.50 | 2,331,722 |
Latest VolitionRX Limited News
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
PR Newswire
3 months ago
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
PR Newswire
3 months ago
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
Zacks Small Cap Research
3 months ago
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis.
PR Newswire
4 months ago
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
GuruFocus.com
4 months ago
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones
Associated Press Finance
4 months ago
VolitionRX: Q1 Earnings Snapshot
PR Newswire
4 months ago
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
GuruFocus.com
4 months ago
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For
Compare VNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.